Trial Profile
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Capivasertib (Primary) ; Cediranib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 12 Dec 2023 Primary endpoint has not been met, (Progression-free survival), as per Results published in the Cancer
- 12 Dec 2023 Results published in the Cancer
- 30 Jun 2023 Status changed from recruiting to active, no longer recruiting.